Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

300 Results

Guidelines and Advice

Optimizing Ambulatory Systemic Treatment Models of Care

Status: Current
Version: 1

Jul 2023

Guidelines and Advice

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

Status: Current
Version: 1

Apr 2023

Guidelines and Advice

Consensus-based organizational guideline for the planning and delivery of spine stereotactic body radiotherapy treatment in Ontario

Status: Current
ID: GL 21-6

Apr 2023

Guidelines and Advice

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Status: Current
ID: GL-END-C50-35

Aug 2023

Drug

regorafenib

Other Name(s): Stivarga®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Nov 2023

Guidelines and Advice

Management of Early-Stage Hodgkin Lymphoma

Status: Current
ID: GL 6-20
Version: 2

May 2023

Guidelines and Advice

The Role of Endolaryngeal Surgery (With or Without Laser) versus Radiotherapy in the Management of Early (T1) Glottic Cancer

Status: Current
ID: 5-2
Version: 2

Oct 2023

Guidelines and Advice

The Management of Head and Neck Cancer in Ontario

Status: Archived
ID: 5-3

Dec 2009

Guidelines and Advice

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Current
ID: GL-END 3-25

Nov 2023

Guidelines and Advice

Rituximab in Chronic Lymphocytic Leukemia

Status: Archived
ID: CED 15

Nov 2009

Guidelines and Advice

Stem Cell Transplantation in Adults

Status: Archived
ID: SCT

Jan 2009

Guidelines and Advice

High-Intensity Focused Ultrasound for Prostate Cancer

Status: Archived
ID: 3-16

Jul 2009

Pages